reproducible assays. Moreover, we agree with Martinelli et al 1 that the level of minimal residual disease (MRD) observed during CR is critically determined by the timing of bone marrow sampling as well as by the chemotherapy protocol adopted (ie standard vs high doses of ARAC). In this connection, we have recently updated our preliminary results 3 of quantitative MRD after induction and consolidation in patients treated with standard doses of ARAC: after induction, 6/7 patients with 4100 copies of leukemic transcript relapsed compared to 2/12 with o100 copies (P ¼ 0.003): moreover, after consolidation, 8/ 11 patients with 410 copies vs 2/12 with o10 copies (P ¼ 0.006) relapsed. It could be interesting to ascertain if similar results were found in patients treated with high-dose ARAC regimens as in the protocol employed by Martinelli et al; 1 nevertheless, our results suggest that early monitoring of MRD after induction or consolidation therapy is predictive of relapse, thus allowing timely treatment changes to overcome resistant disease. In conclusion, we believe that available data of realtime PCR of inv(16) leukemia are by now relevant to the patients outcome and treatment, aiding clinicians to implement more tailored therapeutic approaches.
TO THE EDITOR Cyclin D1 controls the early phase of cell cycle, and overexpression of cyclin D1 is associated with the pathogenesis of Bcell disorders such as mantle cell lymphoma (MCL), hairy cell leukemia (HCL) and multiple myeloma (MM). Several molecular mechanisms including the t(11;14)(q13;q32) could account for the activation of the CCND1 gene and the subsequent expression of cyclin D1. The human CCND1 gene encoding cyclin D1 spans 15 kb, includes five exons and four introns, and generates two major mRNAs of 1.7 and 4.4 kb that differ in their 3 0 -part, the 3 0 UTR region being absent in the shorter form. Thus, cyclin D1 form [b] transcript could be present in t(11;14)(q13;q32)-bearing B-malignancies (Karpas 620) in good correlation with a previous report, 3 and also in cell lines harboring either an insertion of a switch region (U266) or a trisomy of chromosome 11 (NCI H929 and RPMI 8226). 4 There is no correlation between the presence of form [b] transcript and the mechanism of gene activation, and the two alternative form These combined results unambiguously demonstrate the absence of the cyclin D1 form [b] protein in Karpas 620 cells, although they did contain significant amounts of the corresponding mRNA. To our knowledge, the presence of cyclin D1 form [b] has been reported in the Karpas 620 cell line 6 and in three t(11;14)(q13;q32)-positive cell lines. 3 Analysis of cyclin D1 protein was performed with the DCS-6 Ab, which displays no cross-reactivity with other cyclin proteins, but in experimental conditions generating high background. 3, 6 This probably leads to a misinterpretation of the results. By contrast, cyclin D1 protein form [b] was Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder usually associated with small cell lung cancer. It is clinically presented with proximal muscle weakness and autonomic dysfunction. Myasthenic weakness is caused by reduction of acetylcholine release induced by an immune response directed against the calcium channel complex of the nerve terminal. The diagnosis of LEMS is made on the basis of the clinical findings and the characteristic electromyographic patterns. 1 We report on a case of LEMS complicating HCL without evidence of small cell lung cancer. To our knowledge, this is the first case of LEMS described in the context of HCL.
In November 1991, a 70-year-old nonsmoker man presented with pancytopenia and splenomegaly. Following male bone marrow aspiration and biopsy, a diagnosis of HCL was made on the basis of typical morphological, cytochemical and immunophenotypic findings. A thorough investigation for hairy cells in the peripheral blood was unsuccessful. Interferon-a2b was administered (5 million units three times a week). In October 1997, bone marrow aspiration and biopsy showed no evidence of hairy cells and interferon was discontinued. Sustained disease remission was achieved for the four ensuing years, confirmed by careful clinical survey and sequential bone marrow biopsies.
In December 2001, he presented with a 6-month history of severe fatigue, proximal muscle weakness in the arms and legs that increased in the early morning and diminished during the day, dysphonia with nasal speech, difficulties in swallowing and dry mouth. Physical examination revealed diminished tendon reflexes. Cranial nerve functions were preserved. Neither focal neurologic deficits nor eyelid ptosis were noted on neurologic examination. The patient could rise from a chair by the third attempt using his hands. Sensory and motor conduction velocities were normal with a small compound muscle action potential. The compound muscle action potentials recorded from the abductor pollicis brevis and the abductor digiti minimi muscles showed a decrement with repetitive nerve stimulation at low frequencies. During stimulation at high frequencies, the muscle response amplitude increased and became more than twice the size of the initial response, consistent with a diagnosis of LEMS. Antinuclear, gastric parietal cell, mitochondrial, microsomal, smooth muscle, antineuronal, cardiolipin, thyroid and acetylcholine receptor binding autoantibodies were all negative. TSH, B 12 , complement components and immunoelectrophoresis were normal. The direct antiglobulin test was negative. Calcium channel-binding antibodies were not tested. Extensive imaging studies have not demonstrated any type of carcinoma.
Morphological study of the bone marrow biopsy revealed small aggregates from lymphoid cells with reniform and ovale nuclei and typical cytoplasmic configurations of hairy cells (20-25% lymphoid infiltration of the bone marrow), erythroid hyperplasia and increase in reticulin fibers. The immunostaining of bone marrow biopsy on paraffin-embedded sections was positive for leucocyte common antigen, and evaluation of lymphoid subsets showed a lymphoid cell immunoreactivity for CD20/L26 as well as a double population of DBA44 positive and negative cells. Lymphocytes were negative for CD3 immunostaining. All the above findings were consistent with a relapse of HCL. No peripheral blood count abnormalities were noted. An exhaustive search for leukemic cells in the peripheral blood was unsuccessful.
The patient was treated with a single course of 2-chlorodeoxyadenosine at 0.1 mg/kg/day, for 7 days in a continuous intravenous infusion for HCL and with pyridostigmine (120 mg/day) for LEMS. He was discharged and was followed as an outpatient. At the 6-month post-treatment follow-up, he achieved remission of HCL and improvement of his proximal muscle weakness, but no change in voice disturbance and dysphagia. His condition remained stable thereafter.
In most LEMS cases associated with cancer, the cancer is discovered either at the time of diagnosis or within the first 2 years after diagnosis of LEMS. 1 In the current case, coexistence of a second malignancy (small cell lung cancer) was not evident within 1 year from the development of neurologic symptoms despite thorough investigation. Even if the development in the future of a second malignancy could not be excluded, this seems to be unlikely.
